Based on the Jaguar Animal Health Inc stock forecast from 0 analysts, the average analyst target price for Jaguar Animal Health Inc is not available over the next 12 months. Jaguar Animal Health Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Jaguar Animal Health Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Jaguar Animal Health Inc’s stock price was USD 5.05. Jaguar Animal Health Inc’s stock price has changed by +8.03% over the past week, +774.35% over the past month and -96.26% over the last year.
No recent analyst target price found for Jaguar Animal Health Inc
No recent average analyst rating found for Jaguar Animal Health Inc
Company Overview Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. Read Less
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health...Read More
Frequently Asked Questions About Jaguar Animal Health Inc (JAGX) Stock
Stock Target Advisor's fundamental analysis for Jaguar Animal Health Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on JAGX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on JAGX's stock to indicate what its average analyst target is.
JAGX stock's Price/Earning ratio is 0.00.
Our analysis grades JAGX stock's Price / Earning ratio at A-. This means that JAGX stock's Price/Earning ratio is above 7.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this JAGX may be undervalued for its sector.
The last closing price of JAGX's stock was USD 5.05.
The most recent market capitalization for JAGX is USD 3.79M.
Unfortunately we do not have enough analyst data on JAGX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Jaguar Animal Health Inc's stock.
As per our most recent records Jaguar Animal Health Inc has 49 Employees.
Jaguar Animal Health Inc's registered address is 200 Pine Street, San Francisco, CA, United States, 94104.
You can get more information about it from Jaguar Animal Health Inc's website at https://jaguar.health.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Jaguar Animal Health Inc (JAGX) Stock
Stock Target Advisor's fundamental analysis for Jaguar Animal Health Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on JAGX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on JAGX's stock to indicate what its average analyst target is.
JAGX stock's Price/Earning ratio is 0.00.
Our analysis grades JAGX stock's Price / Earning ratio at A-. This means that JAGX stock's Price/Earning ratio is above 7.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this JAGX may be undervalued for its sector.
The last closing price of JAGX's stock was USD 5.05.
The most recent market capitalization for JAGX is USD 3.79M.
Unfortunately we do not have enough analyst data on JAGX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Jaguar Animal Health Inc's stock.
As per our most recent records Jaguar Animal Health Inc has 49 Employees.
Jaguar Animal Health Inc's registered address is 200 Pine Street, San Francisco, CA, United States, 94104.
You can get more information about it from Jaguar Animal Health Inc's website at https://jaguar.health.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for JAGX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
